

ersonal use only

Financial Results Presentation FY25

5 August 2025

Vitrafy Life Sciences Limited (ASX: VFY)
ACN 622 720 254

vitrafy.com
Strictly Private & Confidential



Important Notice and Disclaimer

This presentation is provided by Vitrafy Life Sciences Limited (ACN 622 720 254) (the Company). Statements in this presentation are made only as at the date of this presentation and the information in this presentation remains subject to change without notice. The information in this presentation is of a general nature and does not purport to be complete, is provided solely for information purposes of giving you summary information and background about the Company and its activities, current as at 5 August 2025, and should not be relied upon by the recipient.

This presentation is not, and does not constitute, or form any part of, an offer to sell or issue, or the solicitation, invitation or recommendation to purchase any securities.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation.

This presentation does not purport to summarise all information that a recipient should consider when making an investment decision, and should not form the basis of any decision by a recipient.

Recipients should carry out their own investigations and analysis of the Company and verify the accuracy, reliability and completeness of the information contained in this presentation or any other form of communication to which the recipient is permitted access in the course of evaluating an investment in the Company.

No liability

To the maximum extent permitted by law, the Company, or their respective affiliates or related bodies corporate or any of their respective officers, directors, employees, agents and advisers (Related Parties), nor any other person, accepts any responsibility or liability for, and makes no recommendation, representation or warranty concerning, the content of this presentation, the Company, or the Company's securities including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it.

Eligible recipients

This presentation is provided to you as an investor to whom an offer document is not required to be given, and no registration, lodgement or other formality is required, in connection with an offer of securities. In accepting this presentation you warrant that you are an investor within the scope of this paragraph and that you accept this presentation on the basis set out in this notice.

This presentation is not, and does not constitute, or form any part of, an offer to sell or the solicitation, invitation or recommendation to purchase any securities in the United States and neither this presentation nor anything contained herein shall form the basis of any contract or commitment. This presentation may not be distributed or released in the United States. Securities may not be offered or sold in the United States unless such securities are registered under the U.S. Securities Act of 1933, as amended (U.S. Securities Act) or in a transaction exempt from, or not subject to, the registration requirements of the U.S. Securities Act and any other applicable securities laws. Each institution or person that reviews this presentation will be deemed to represent that each such institution or person is not in the United States.

The distribution of this presentation may be restricted by law. Persons who come into possession of this presentation should seek advice and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws.

Confidentiality

This presentation is confidential and not for further distribution. It is provided by the Company on the basis that, by accepting this presentation, persons to whom this presentation is given agree to keep the information confidential, not copy the presentation and not to disclose it, in whole or in part, to anyone within their organisation except on a need-to-know basis and subject to these restrictions, or to anyone outside their organisation.

Important Notice and Disclaimer (cont.)

Not financial product advice

Reliance should not be placed on the information or opinions contained in this presentation. This presentation is for informational purposes only and is not financial product or investment advice or a recommendation to acquire the Company's securities and does not take into consideration the investment objectives, financial situation or particular needs of any particular investor. You should make your own assessment of an investment in the Company and should not rely on this presentation. In all cases, you should conduct your own research of the Company and analysis of the financial condition, assets and liabilities, financial position and performance, profits and losses, prospects and business affairs of the Company and its business, and the contents of this presentation. You should seek legal, financial, tax and other advice appropriate to your jurisdiction.

Past performance

Past performance information given in this presentation is given for illustrative purposes only and should not be relied upon as an indication of (and gives no guidance as to) future performance.

Future performance

This presentation contains certain forward-looking statements (including financial forecasts) with respect to the financial condition, operations and business of the Company and certain plans and objectives of the management of the Company. Forward-looking statements can be identified by the use of forward-looking terminology, including, without limitation, the terms "believes", "estimates", "anticipates", "expects", "predicts", "intends", "plans", "goals", "targets", "aims", "outlook", "guidance", "forecasts", "may", "will", "would", "could" or "should" or, in each case, their negative or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts.

Such forward looking statements involve known and unknown risks, uncertainties and other factors which because of their nature may cause the actual results or performance of the Company to be materially different from the results or performance expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the political and economic environment in which the Company will operate in the future, which may not be reasonable, and are not guarantees or predictions of future performance. No representation is made that any of these statements or forecasts will come to pass or that any forecast result will be achieved, or that there is a reasonable basis for any of these statements or forecasts.

Forward-looking statements speak only as at the date of this presentation and to the full extent permitted by law, the Company and its respective affiliates and related bodies corporate and each of their respective Related Parties and intermediaries disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, but not limited to, any assumptions or expectations set out in the presentation).

Financial data

All figures in the presentation are Australian dollars (\$) or A\$) unless stated otherwise. A number of figures, amounts, percentages, estimates, calculations of value and fractions in this presentation are subject to the effect of rounding. Accordingly, the actual calculation of these figures may differ from the figures set out in this presentation.

Financial information

The pro forma financial information provided in this presentation is for illustrative purposes only and does not represent a forecast or expectation as to the Company's future financial condition and/or performance. This document has been prepared at a time where the review of financial information contained in this presentation has not been completed and accordingly, you should only rely on any expectation as to the Company's future financial condition and/or performance that is contained in a prospectus or other offering document which may be issued by the Company in connection with any offer of the Company's securities.

Acknowledgement

Persons who access, receive, review or attend this presentation are required to inform themselves of, and comply with, all of the above restrictions and prohibitions and none of the Company or the Related Parties accepts any liability to any person in relation thereto. This presentation is made to you on the basis that by attending, accessing or receiving or reviewing this presentation, you confirm that you understand and agree to the contents of this important notice and disclaimer and that you are a person to whom this presentation may lawfully be made in accordance with laws applicable to you, including those of the jurisdiction in which you are located.

Today's Presenters



Brent Owens

Chief Executive Officer (from 1 September 2025), Co-Founder

Creative entrepreneur and co-inventor of Vitrafy's technology, with extensive expertise in intellectual property development. He has played a pivotal role in pioneering Vitrafy's technological innovations and securing supporting patent protection. Brent is responsible for developing the strategic vision for Vitrafy, ensuring the alignment of its technology innovations with commercial opportunities. In 2023, Brent was recognized as the runner-up for Biotechnology Pioneer of the Year at the AmCham Alliance Awards.



Kate Munnings

Chief Executive Officer (until 1 September 2025)

Extensive experience across the healthcare industry, most recently as Managing Director and Chief Executive Officer of Virtus Health Limited (previously ASX:VRT), one of the largest global providers of assisted reproductive services. Prior to this, Kate was Chief Operating Officer of Ramsay Health Care (ASX:RHC). Kate is also Chair of the Digital Health Cooperative Research Centre and a Non-Executive Director of Ryman Healthcare Limited (NZX:RYM) and Wesfarmers Limited (ASX:WES).



Simon Martin

Chief Financial Officer

25 years' experience in executive and non-executive roles across private, ASX-listed, and private equity-owned organisations. Simon's background encompasses finance and strategic roles in the software sector in Australia and internationally. Deep executive experience, including as Chief Executive Officer at iCareHealth and Chief Financial Officer at MYOB Ltd (formerly ASX:MYO). Simon has a Bachelor of Commerce and MBA from University of Melbourne and is a member of the AICD.



Sonia Petering

Chair

Extensive experience as a non-executive director and board chair in various highly regulated sectors. Sonia is currently, a member of the University of Melbourne Law School Foundation, and a councillor of the Victorian Division of the Australian Institute of Company Directors. Sonia previously served as Chair of QANTM IP Ltd (previously ASX:QIP), Chair of Virtus Health Ltd (previously ASX:VRT), and Chair of Rural Finance Corporation of Victoria. Sonia is Principal of her own legal practice. She holds a Bachelor of Laws and Bachelor of Commerce from the University of Melbourne.



Vitrafy addresses the vital global need for enhanced cryopreservation solutions.



Vitrafy's mission is to improve the quality of healthcare treatments by providing effective cryopreservation technology, preserving life.

1

Results and Operational Overview

FY25 Delivered on IPO Commitments

Operational Highlights

Market development

Progress in FY25

- Expansion of commercial activity in animal reproduction, with significant interest for market development from key players in this space
- Pipeline growth in all application areas – blood, cell and gene therapies
- U.S. operations and business development capability established. Further recruitment underway
- Value proposition studies (human health) meeting partner expectations
- Phase 1 blood platelets study complete (USAISR), exceeding standards

Technology development

Progress in FY25

- VCU2 detailed design well advanced, with build phase commencing now
- Regulatory framework developed, with unregulated market product release on track for 2Q FY26
- LifeChain™ software upgrade progressing well with first significant release in line with VCU2
- Testing with collaboration partners through the year continued to prove out the technology delivery model

Financial Position

\$29.6m


Total cash and liquid assets

\$4.8m


Commercialisation grant awarded

Market Development


Quality and Consistency



Animal Reproduction





Blood & Blood Products



Cell & Gene Therapies

Commercialisation and Priority Applications



Vitrafy's next-generation cryopreservation technology has widespread applications across a variety of biological materials.



Market	Bovine & aquaculture	Blood platelets	Cell & gene therapy
Regulatory status	Global Market Unlocked – Immediate	Unregulated unlocked – Q2 FY26 Regulated unlocked – H2 FY26 (USA)	Unregulated unlocked – Q2 FY26 Regulated unlocked – H2 FY26 (USA)
Users	<ul style="list-style-type: none"> • Animal Semen suppliers • Equipment Manufacturers & Distributors 	<ul style="list-style-type: none"> • Blood Collection & Production Centres • Bio-banks • Research and Academia 	<ul style="list-style-type: none"> • Biotechnology and Biopharmaceutical companies in early-stage clinical trials • Raw Material points of collection • Contract Development & Manufacturing Organisations (CDMO) • Research and Academia

Operational Highlights – Blood Platelets

Completed third party studies on commercial scale volumes; progressing towards commercialisation with partner, U.S Military



Phase 1 Study results completed with U.S. Military

Completed Phase 1 Study with outstanding results

'Game-changing' opportunity in platelet

Study results published in leading military journal, *Combat & Casualty Care*

Executed Phase 2 SOW, to commence in Q1 FY26


Operational Highlights – Blood Platelets

“

Despite the limited sample size of our initial phase 1 study, our results suggest that cryopreserved platelets have the potential to be game changer for Warfighters, especially in Large Scale Combat Operations and resource constrained environments.

– Says Cardenas.

”



PLATELET CRYOPRESERVATION MOVES CLOSER TO PRACTICALITY

U.S. Army Institute of Surgical Research and Vitrafy are teaming up to evaluate an innovative method for preserving blood cells that control clotting.

By Paul Lagasse, DMA PhD-MDCC



Further endorsement of Vitrafy technology from U.S. Military via co-presentation of study abstract at multiple blood conferences in the short term.



MILITARY HEALTH SYSTEM

MHSRS


RESEARCH SYMPOSIUM




Association for the
Advancement of
Blood & Biotherapies

Operational Highlights – Cell and Gene Therapies

Vitrafy technology proven to exceed current industry standards – established a data set critical for market penetration.



PBMC* Validation Data (raw material)



* PBMCs are a critical starting raw material for Cell and Gene Therapy manufacturing. The quality, consistency and viability of these materials directly impact therapeutic outcomes.


Internal testing proves Vitrafy's value proposition in priority market segments far exceeds market standards

Continuing to build application data sets that support the presentation to market


Foundations set for revenue generating collaborations – Vitrafy engaging with several potential partners

Operational Highlights – Aquaculture

Growth in commercialisation with existing and new partners; validated competitive advantage.



Aquaculture Comparison Study Q3 & Q4 FY25



Post Thaw Fertilisation Median Result

Fresh: 74.5%

Vitrafy: 70.2%

Competitor: 49.4%

■ Vitrafy ■ Fresh ■ Competitor

X in Box = mean score for data set. Fresh mean = 72.4%

VFY mean = 68.2% | Competitor mean: 47.1%


Revenue growth in commercial activities

Consistent fertilisation outcomes across multiple FY25 cycles


Paid pilot with second domestic provider

Operational Highlights – Bovine

Value proposition proven;
exploring global market
opportunities



Post Thaw Recovered Semen Motility




Continuing to build application data sets that support the presentation to market

Continuing collaboration – onsite trials ongoing with Select Sires, Inc.

Exploring global market opportunities in animal reproduction that includes Bovine

Commercialisation Approach

Vitrafy has developed a staged pipeline to progress its innovative technology with partners to a point of commercialisation.



Quality and
Consistency

Technology Development





LifeChain^o



Quality and
Consistency

Operational Highlights – Hardware (VCU2)

Vitrafy has designed a commercial-ready product with a competitive edge

Continued innovation, building on the competitive advantage and IP 'moat'

Increased performance and expanded functionality

Increased reliability through refrigeration system optimisation

Commenced planning for scaled manufacturing capability

Worldwide integration via mains power compatibility

Integrated LifeChain software




Awarded
\$4.8m
Grant

from the Australian Industry Growth Fund to support commercialisation and growth of innovative products for Australian companies

Operational Highlights – Hardware (VCU2)

Vitrafy has a clear and defined path to commercialisation in FY26



Operational Highlights – Software

The LifeChain™ upgrade is a critical component in commercialisation, delivering an enterprise-grade software

LifeChain°

Architecture, Infrastructure & Functional Development

Complete

- Building scalable foundations to enable large volumes of data acquisition
- Core functionality to support Commercial objectives
- Cyber security protections to FDA requirements
- VCU2 Control Systems

Current Program of work

Market Release with VCU2

In progress

Enhancing VCU2 functionality and integrations

Commercialisation

- H1 FY26
- Animal Reproduction
- Human Cell & Gene Therapy

2

Financial Results FY25

Income Statement

Summary (\$'000's)	FY24	FY25
Sales revenue	37	65
Interest and Other Income	34	784
Grant Income	-	972
Research and development tax incentive	2,023	983
Total Income	2,094	2,804
Administrative expenses	2,676	7,675
Research and development expenses	4,248	6,563
Other expenses	3,782	2,350
Finance costs	10,432	6,492
Fair value loss/(gain) on embedded derivative	(8,619)	12,434
Total Expenses	12,519	35,515
Loss before income tax expense	(10,425)	(32,710)

Commentary:

- **Sales up 75% YoY**, driven by Huon growth and aquaculture pilot completion.
- **~\$1m IGP grant earned**, \$2.4m cash received; remainder recorded as unearned revenue on the balance sheet.
- **R&D tax incentive declining**, with commercialisation preparation reducing eligibility; new projects possible in FY26, but minimal claims expected.
- **R&D spend expected to be up ~50% in FY26**, 70% front-loaded in 1H; partially offset by IGP grant.
- **\$18.9m non-cash cost** from convertible note conversion at IPO (1H FY25) recognised via one-off finance costs and losses on embedded derivatives.
- **Share-based payments \$2m**, up from \$0.4m, aligned with new executive incentive plan reflected in Administrative Expenditure.

Normalised Income Statement

Summary (\$000's)	1H FY24	2H FY24	FY24	1H FY25	2H FY25	FY25	Normalised Income FY25
Income	1,205	889	2,094	738	2,067	2,804	2,804
Administrative expenses	(1,201)	(1,475)	(2,676)	(3,770)	(3,906)	(7,675)	(5,600)
Research and development expenses	(2,232)	(2,016)	(4,248)	(2,323)	(4,240)	(6,563)	(6,563)
Other expenses	(2,779)	(1,003)	(3,782)	(1,413)	(936)	(2,350)	(1,983)
Finance costs	(4,398)	(6,033)	(10,432)	(6,481)	(11)	(6,492)	-
Fair value (loss)/gain on embedded derivative	9,359	(740)	8,619	(12,434)	-	(12,434)	-
Loss before income tax expense	(47)	(10,379)	(10,425)	(25,684)	(7,027)	(32,710)	(11,342)
Normalisation Adjustments:							
Share based payments	225	115	340	986	1,090	2,076	
Convertible note finance costs	4,398	6,033	10,432	6,481	11	6,492	
Fair value adjustment to convertible notes	(9,359)	740	(8,619)	12,434	-	12,434	
Capital raise costs	1,795	236	2,032	367	-	367	
Normalised Loss before income tax	(2,987)	(3,254)	(6,241)	(5,416)	(5,926)	(11,342)	

Commentary:

- Financial performance for FY24 and FY25 impacted by a series of one-off, cash and non-cash expenditure items:
 - Capital Raising costs:** \$367k expensed in 1H FY25 associated with the IPO process. Removed out of 'Other Expenses'.
 - Convertible Notes Conversion:** \$18.9m of non-recurring, non-cash movements expensed in 1H FY25 reflecting the conversion of the convertible notes.
 - Share Based Payments:** \$2.1m of non-cash share-based payments as part of the Company's Equity Incentive Program.
- Normalised Loss before income tax for FY25 is \$(11.3)m after removing the impact of non-cash and non-recurring items.

Balance Sheet

Summary (\$000's)	FY24 as at 30 June	FY25 as at 30 June
Cash and term deposits	6,413	29,595
Receivables & prepayments	595	673
R&D receivable	2,023	983
Current assets	9,030	31,251
Non-current assets	746	593
Payables & accrued expenses	404	775
Deferred income	-	1,428
Lease liability	83	90
Employee entitlements	434	432
Convertible notes	33,033	-
Current liabilities	33,953	2,724
Non-current liabilities	424	352
Net assets	(24,601)	28,768
Issued capital	5,188	89,685
Reserves	869	2,451
Accumulated losses	(30,658)	(63,368)
Equity	(24,601)	28,768

Commentary:

- **\$29.6m cash and liquid assets** on hand, including \$10.1m in term deposits.
- **Cash runway forecast through to CY2027** with elevated expenditure in FY26.
- Receivables include GST refund, term deposit interest, and **\$623k in Accounts Receivable**.
- Deferred income from \$2.4m IGP grant (matched to spend), with more to come this year.
- **Issued capital** reflects convertible note conversion and IPO raise (Nov 2024).

Cash Flow

Summary (\$000's)	FY24	FY25
Receipts from customers and other income	41	97
Payments to suppliers and employees	(8,879)	(14,078)
Net interest received	34	517
R&D tax incentive received	2,013	2,023
Government grant received	–	2,640
Operating cash flow	(6,792)	(8,801)
Investments in term deposits	–	(10,075)
Payments for property, plant and equipment	(13)	(2)
Investing cash flow	(13)	(10,077)
Proceeds from issue of shares	268	35,000
Exercise of options	–	317
Proceeds from issue of convertible notes	12,000	–
Capital raising costs	(639)	(3,249)
Shareholder loans	–	–
Repayment of lease liabilities	(133)	(83)
Financing cash flow	11,496	31,986
Net cash flow	4,692	13,108
Closing cash	6,413	19,520
Term deposits	–	10,075
Cash & Liquid Assets	6,413	29,595

Cash and Liquid Assets refers to cash on hand and term deposits held by the Company

3

Outlook

FY26 Outlook

Vitrafy has a clear focus on revenue-generating commercialisation activities

Market development



Capture global commercial opportunities in animal reproduction



Expand paid human health collaborations



Complete Phase 2 blood platelets study; progress to commercialisation



Aggressively scale U.S. operations and team development

Technology development



Unregulated product launch H1 FY26



Medical Device product launch H2 FY26



Build supply chain and manufacturing capability and capacity

Questions



Thank You

Contacts

Mr. Brent Owens

Chief Executive Officer (from 1 September 2025), Co-Founder

Email: bowens@vitrafy.com

Simon Martin

Chief Financial Officer

Email: smartin@vitrafy.com

Vitrafy Life Sciences Limited (ASX: VFY)
ACN 622 720 254

vitrafy.com

Strictly Private and Confidential